-+ 0.00%
-+ 0.00%
-+ 0.00%

RedHill Biopharma publishes corporate presentation on GI, infectious disease and oncology pipeline

PUBT·04/19/2026 18:16:57
Listen to the news
RedHill Biopharma publishes corporate presentation on GI, infectious disease and oncology pipeline
  • RedHill Biopharma highlighted Talicia as its marketed product, supported by a U.S. co-commercialization partnership with Cumberland Pharma.
  • Net revenues totaled USD 4.1 million in H1 2025.
  • Cash balance was USD 3 million as of June 30, 2025.
  • Equity financing capacity was USD 31.7 million as of December 2025.
  • Pipeline focus included RHB-102 (Bekinda) with a completed first U.S. Phase 3 study in gastroenteritis and gastritis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief on April 19, 2026, and is solely responsible for the information contained therein.